Australian biotech market today 13.03.09
Friday, 13 March, 2009
Biotech and pharma stocks were up 1.5 per cent on trading at 2pm compared to a rise in the All Ordinaries of three per cent, on a good day for the Australian sharemarket overall.
Alchemia (ASX:ACL) is up 5c on news that its manufacturing partner Dr Reddy’s Laboratories had filed a new drug application with the US FDA for a generic version of fondaparinux, an anti-coagulant used for treating blood clots.
pSivida (ASX:PVA) was up eight per cent to $1 following its report of good interim results in a Phase II trial of an intra-vitreal insert for diabetic macular oedema.
CSL (ASX:CSL) is up 40c but is still down on its year high of $38.50, while Sonic Healthcare recovered 40c on yesterday’s year low of $9.96.
Acrux (ASX:ACR) and Cellestis (ASX:CST) were up slightly on very small volumes.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
